dr. weber on risk and benefits with immunotherapy combos in melanoma
Published 7 years ago • 188 plays • Length 1:03Download video MP4
Download video MP3
Similar videos
-
1:16
dr. weber on emerging immunotherapy combinations in melanoma
-
2:25
dr. weber on discontinuing immunotherapy in melanoma
-
1:46
dr. weber on selecting immunotherapy for patients with melanoma
-
0:49
dr. weber on emerging therapies in melanoma
-
1:22
dr. weber on adjuvant pembrolizumab in melanoma
-
1:58
dr. weber on duration of checkpoint inhibitor therapy in melanoma
-
2:06
dr. weber on next steps with pembrolizumab as melanoma treatment
-
2:10
dr. weber on the toxicity profile of nivolumab versus ipilimumab for melanoma
-
1:13
dr. weber on growing costs with triplet and four-drug regimens in melanoma
-
6:56
emerging immunotherapy combinations for melanoma
-
2:05
dr. weber on adjuvant approaches in stage iii melanoma
-
1:44
dr. jeffrey weber on optimal therapy sequences in advanced melanoma
-
0:57
dr. weber on fda approval of pembrolizumab for stage iii melanoma
-
3:40
aacr 2023 highlights on advances in the treatment of resected high-risk melanoma with jeffrey weber
-
1:22
dr. weber on nivolumab versus chemotherapy in advanced melanoma
-
1:15
dr. weber on nivolumab in the adjuvant setting for melanoma
-
1:36
dr. weber on combination strategies for braf-mutant melanoma
-
1:08
dr. weber discusses toxicity of immunotherapies in melanoma
-
7:00
metastatic melanoma: the immunotherapy approach